Aura Biosciences (NASDAQ:AURA) Stock Craters; Here’s Why
Market News

Aura Biosciences (NASDAQ:AURA) Stock Craters; Here’s Why

Shares of Aura Biosciences (NASDAQ:AURA) fell more than 20% during Monday’s trading session. This can be attributed to news of the company’s trial results for belzupacap sarotalocan, its eye cancer candidate.

The patients in the study saw an almost 89% tumor control rate. Indeed, the slowdown in tumor growth rate was statistically significant. Nonetheless, an unrelated adverse event caused one patient to stop the trial.

Is AURA Stock a Buy?

Turning to Wall Street, AURA stock has a Moderate Buy consensus rating based on two Buys assigned in the past three months. The average Aura stock price target of $28 implies 93.5% upside potential.

Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
RUT
Russell 2000
TNX
10-Yr-Bond
Bitcoin

Popular Articles